These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 31926199)

  • 1. The therapeutic potential of second and third generation CB
    Cinar R; Iyer MR; Kunos G
    Pharmacol Ther; 2020 Apr; 208():107477. PubMed ID: 31926199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral CB1R as a modulator of metabolic inflammation.
    Han JH; Kim W
    FASEB J; 2021 Apr; 35(4):e21232. PubMed ID: 33715173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.
    Takano A; Gulyás B; Varnäs K; Little PB; Noerregaard PK; Jensen NO; Elling CE; Halldin C
    Synapse; 2014 Mar; 68(3):89-97. PubMed ID: 24293119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice.
    Han JH; Shin H; Park JY; Rho JG; Son DH; Kim KW; Seong JK; Yoon SH; Kim W
    FASEB J; 2019 Mar; 33(3):4314-4326. PubMed ID: 30566396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.
    Cinar R; Iyer MR; Liu Z; Cao Z; Jourdan T; Erdelyi K; Godlewski G; Szanda G; Liu J; Park JK; Mukhopadhyay B; Rosenberg AZ; Liow JS; Lorenz RG; Pacher P; Innis RB; Kunos G
    JCI Insight; 2016 Jul; 1(11):. PubMed ID: 27525312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological comparison of traditional and non-traditional cannabinoid receptor 1 blockers in rodent models in vivo.
    Varga B; Kassai F; Szabó G; Kovács P; Fischer J; Gyertyán I
    Pharmacol Biochem Behav; 2017 Aug; 159():24-35. PubMed ID: 28666894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral Hybrid CB
    Zawatsky CN; Park JK; Abdalla J; Kunos G; Iyer MR; Cinar R
    Front Endocrinol (Lausanne); 2021; 12():744857. PubMed ID: 34650521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.
    Cooper ME; Regnell SE
    Br J Clin Pharmacol; 2014 Jan; 77(1):21-30. PubMed ID: 23452341
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Hirsch S; Tam J
    Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31096702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CB
    Drori A; Gammal A; Azar S; Hinden L; Hadar R; Wesley D; Nemirovski A; Szanda G; Salton M; Tirosh B; Tam J
    Elife; 2020 Nov; 9():. PubMed ID: 33210603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier.
    Wu YK; Yeh CF; Ly TW; Hung MS
    Curr Top Med Chem; 2011; 11(12):1421-9. PubMed ID: 21510837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.
    Knani I; Earley BJ; Udi S; Nemirovski A; Hadar R; Gammal A; Cinar R; Hirsch HJ; Pollak Y; Gross I; Eldar-Geva T; Reyes-Capo DP; Han JC; Haqq AM; Gross-Tsur V; Wevrick R; Tam J
    Mol Metab; 2016 Dec; 5(12):1187-1199. PubMed ID: 27900261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications.
    Kunos G; Tam J
    Br J Pharmacol; 2011 Aug; 163(7):1423-31. PubMed ID: 21434882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of targeting the peripheral endocannabinoid/CB
    Tam J; Hinden L; Drori A; Udi S; Azar S; Baraghithy S
    Eur J Intern Med; 2018 Mar; 49():23-29. PubMed ID: 29336868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: past, present and future.
    Simon V; Cota D
    Eur J Endocrinol; 2017 Jun; 176(6):R309-R324. PubMed ID: 28246151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists.
    Janero DR
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):17-29. PubMed ID: 22335400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.
    Nguyen T; Thomas BF; Zhang Y
    Curr Top Med Chem; 2019; 19(16):1418-1435. PubMed ID: 31284863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel mouse and rat CB1R isoforms and in silico modeling of human CB1R for peripheral cannabinoid therapeutics.
    Liu QR; Huang NS; Qu H; O'Connell JF; Gonzalez-Mariscal I; Santa-Cruz-Calvo S; Doyle ME; Xi ZX; Wang Y; Onaivi ES; Egan JM
    Acta Pharmacol Sin; 2019 Mar; 40(3):387-397. PubMed ID: 30202012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic targeting of the centrally active cannabinoid 1 receptor (CB
    Hirsch S; Hinden L; Naim MB; Baraghithy S; Permyakova A; Azar S; Nasser T; Portnoy E; Agbaria M; Nemirovski A; Golomb G; Tam J
    J Control Release; 2023 Jan; 353():254-269. PubMed ID: 36442615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox.
    Dao M; François H
    Front Endocrinol (Lausanne); 2021; 12():720734. PubMed ID: 34305821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.